Esophagus Adenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: ESP025 MIFTS: 43	Esophagus Adenocarcinoma Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma ¹² ¹⁵

Adenocarcinoma of Esophagus ⁴⁵ ⁷⁴

Oesophageal Adenocarcinoma ¹²

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:4914

MeSH ⁴⁵ C562730

NCIt ⁵¹ C4025

UMLS ⁷⁴ C0279628

Sources

Summaries for Esophagus Adenocarcinoma

Disease Ontology : ¹² An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to adenocarcinoma and barrett esophagus. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1), and among its related pathways/superpathways are Gastric cancer and Colorectal Cancer Metastasis. The drugs leucovorin and Irinotecan have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and colon, and related phenotypes are digestive/alimentary and endocrine/exocrine gland

Sources

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 144)

#	Related Disease	Score	Top Affiliating Genes
1	adenocarcinoma	30.2	ERBB2 HNF1A-AS1 PTGS2 SMAD4 TP53
2	barrett esophagus	30.1	CDX2 ERBB2 PTGS2 TP53
3	gastroesophageal reflux	29.8	CDX2 PTGS2 TP53
4	adenoma	29.7	PTGS2 SMAD4 TP53
5	squamous cell carcinoma	29.6	ERBB2 HNF1A-AS1 PTGS2 SMAD4 TP53
6	gastric adenocarcinoma	29.0	CDX2 ERBB2 PTGS2 SMAD4 TP53
7	esophageal cancer	28.7	CDX2 ERBB2 MIR21 PTGS2 SMAD4 TP53
8	lung cancer	28.2	AFAP1-AS1 ERBB2 HNF1A-AS1 MIR143 MIR145 MIR21
9	gastric cancer	27.3	AFAP1-AS1 CDX2 ERBB2 HNF1A-AS1 MIR143 MIR145
10	gastric papillary adenocarcinoma	10.4	ERBB2 TP53
11	pleomorphic adenoma carcinoma	10.4	ERBB2 TP53
12	non-proliferative fibrocystic change of the breast	10.4	ERBB2 TP53
13	uterine corpus serous adenocarcinoma	10.4	ERBB2 TP53
14	mutyh-associated polyposis	10.4	SMAD4 TP53
15	breast squamous cell carcinoma	10.4	ERBB2 TP53
16	uterine body mixed cancer	10.4	ERBB2 TP53
17	glioma susceptibility 1	10.4	ERBB2 TP53
18	microglandular adenosis	10.4	ERBB2 TP53
19	endocrine gland cancer	10.3	ERBB2 SMAD4 TP53
20	breast benign neoplasm	10.3	ERBB2 TP53
21	breast adenocarcinoma	10.3	ERBB2 SMAD4 TP53
22	thoracic benign neoplasm	10.3	ERBB2 TP53
23	nasal cavity adenocarcinoma	10.2	CDX2 TP53
24	uterine corpus cancer	10.2	ERBB2 TP53
25	vulva adenocarcinoma	10.2	CDX2 ERBB2
26	leukemia, chronic lymphocytic 2	10.2	MIR143 MIR145 TP53
27	biliary papillomatosis	10.2	CDX2 TP53
28	tongue squamous cell carcinoma	10.2	AFAP1-AS1 MIR21 TP53
29	hidradenocarcinoma	10.2	CDX2 ERBB2 TP53
30	endocervical adenocarcinoma	10.1	CDX2 TP53
31	protoplasmic astrocytoma	10.1	PTGS2 TP53
32	ovarian serous carcinoma	10.1	MIR143 MIR145 MIR21
33	recurrent respiratory papillomatosis	10.1	PTGS2 TP53
34	helicobacter pylori infection	10.1
35	fungal esophagitis	10.1	ATP12A ATP4A
36	diclofenac allergy	10.1	ATP12A ATP4A
37	gastroduodenal crohn's disease	10.1	ATP12A ATP4A
38	neonatal candidiasis	10.1	ATP12A ATP4A
39	squamous papillomatosis	10.1	ATP12A ATP4A
40	toxic megacolon	10.1	ATP12A ATP4A
41	aspiration pneumonitis	10.1	ATP12A ATP4A
42	gastrointestinal neuroendocrine benign tumor	10.1	ATP12A ATP4A
43	gastric antral vascular ectasia	10.1	ATP12A ATP4A
44	granulomatous gastritis	10.1	ATP12A ATP4A
45	esophageal candidiasis	10.1	ATP12A ATP4A
46	gastric neuroendocrine neoplasm	10.1	ATP12A ATP4A
47	acute laryngitis	10.1	ATP12A ATP4A
48	laryngitis	10.0	ATP12A ATP4A
49	duodenitis	10.0	ATP12A ATP4A
50	rumination disorder	10.0	ATP12A ATP4A

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:

Sources

Symptoms & Phenotypes for Esophagus Adenocarcinoma

MGI Mouse Phenotypes related to Esophagus Adenocarcinoma:

⁴⁷

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.7	ATP12A ATP4A CDX2 ERBB2 PTGS2 SMAD4
2	endocrine/exocrine gland	MP:0005379	9.5	ATP4A CDO1 CDX2 ERBB2 PTGS2 SMAD4
3	neoplasm	MP:0002006	9.1	ATP4A CDX2 ERBB2 PTGS2 SMAD4 TP53

Sources

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 193)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

leucovorin

Approved

Phase 4,Phase 2,Phase 3,Phase 1

58-05-9

143 6006

Irinotecan

Approved, Investigational

Phase 4,Phase 2,Phase 1

100286-90-6, 97682-44-5

60838

Levoleucovorin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1

68538-85-2

Oxaliplatin

Approved, Investigational

Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable

61825-94-3

43805 6857599 5310940 9887054

Fluorouracil

Approved

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

51-21-8

3385

Calcium

Approved, Nutraceutical

Phase 4,Phase 3,Phase 2,Phase 1

7440-70-2

271

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 4,Phase 2,Phase 3,Phase 1

59-30-3

6037

Liver Extracts

Phase 4,Phase 2,Phase 1

Immunologic Factors

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Antidotes

Phase 4,Phase 2,Phase 3,Phase 1

Protective Agents

Phase 4,Phase 2,Phase 3,Phase 1

Antimetabolites, Antineoplastic

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

topoisomerase I inhibitors

Phase 4,Phase 2,Phase 1

Immunosuppressive Agents

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Antimetabolites

Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Calcium, Dietary

Phase 4,Phase 3,Phase 2,Phase 1

Topoisomerase Inhibitors

Phase 4,Phase 3,Phase 2,Phase 1

Folate

Phase 4,Phase 2,Phase 3,Phase 1

Vitamin B9

Phase 4,Phase 2,Phase 3,Phase 1

Hormones

Phase 4,Phase 3,Phase 2,Phase 1

Trace Elements

Phase 4,Phase 2,Phase 3,Phase 1

Vitamin B Complex

Phase 4,Phase 2,Phase 3,Phase 1

Vitamins

Phase 4,Phase 2,Phase 3,Phase 1

Micronutrients

Phase 4,Phase 2,Phase 3,Phase 1

Nutrients

Phase 4,Phase 2,Phase 3,Phase 1

Epirubicin

Approved

Phase 3,Phase 2,Phase 1

56420-45-2

41867

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

Esomeprazole

Approved, Investigational

Phase 3

161796-78-7, 161973-10-0, 119141-88-7

9568614 4594

Aspirin

Approved, Vet_approved

Phase 3

50-78-2

2244

Capecitabine

Approved, Investigational

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

154361-50-9

60953

Cetuximab

Approved

Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable

205923-56-4

56842117 2333

Docetaxel

Approved, Investigational

Phase 3,Phase 2,Phase 1

114977-28-5

148124

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Paclitaxel

Approved, Vet_approved

Phase 3,Phase 2,Phase 1

33069-62-4

36314

Gefitinib

Approved, Investigational

Phase 3,Phase 2,Phase 1

184475-35-2

123631

Trioxsalen

Approved

Phase 3,Phase 2

3902-71-4

5585

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3,Phase 2

50-02-2

5743

Ondansetron

Approved

Phase 3

99614-02-5

4595

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3,Phase 2

1177-87-3

Ranitidine

Approved

Phase 3

66357-59-3, 66357-35-5

3001055

Tegafur

Approved, Investigational

Phase 3

17902-23-7

5386

nivolumab

Approved

Phase 2, Phase 3

946414-94-4

Ipilimumab

Approved

Phase 2, Phase 3

477202-00-9

Trastuzumab

Approved, Investigational

Phase 3,Phase 2,Phase 1

180288-69-1

9903

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1,Not Applicable

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Antipyretics

Phase 3

Antacids

Phase 3

Platelet Aggregation Inhibitors

Phase 3,Phase 2

Fibrinolytic Agents

Phase 3

Interventional clinical trials:

(show top 50) (show all 287)

#	Name	Status	NCT ID	Phase	Drugs
1	Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer	Unknown status	NCT00628784	Phase 4
2	Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer	Recruiting	NCT02366819	Phase 4	Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
3	Combination Chemotherapy in Treating Patients With Esophageal Cancer	Unknown status	NCT00041262	Phase 3	cisplatin;epirubicin hydrochloride;fluorouracil
4	A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia	Unknown status	NCT00357682	Phase 3	Esomeprazole;Esomeprazole;Aspirin
5	STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD	Unknown status	NCT02935881	Phase 3
6	Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus	Unknown status	NCT00002884	Phase 3	chemotherapy;cisplatin;fluorouracil
7	Surgery With or Without Combination Chemotherapy in Treating Patients With Cancer of the Esophagus	Unknown status	NCT00002883	Phase 3	cisplatin;fluorouracil
8	Cisplatin, Capecitabine, and Radiation Therapy With or Without Cetuximab in Treating Patients With Esophageal Cancer	Unknown status	NCT00509561	Phase 2, Phase 3	capecitabine;cisplatin
9	Confocal Endomicroscopy for Barrett's Esophagus	Completed	NCT00487695	Phase 3
10	Surgery With or Without Radiation Therapy and Chemotherapy in Treating Patients With Esophageal Cancer	Completed	NCT00047112	Phase 3	cisplatin;fluorouracil
11	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Cancer of the Esophagus	Completed	NCT00002631	Phase 3	chemotherapy;cisplatin;fluorouracil
12	Surgery With or Without Chemotherapy and Radiation Therapy in Treating Patients With Cancer of the Esophagus	Completed	NCT00003118	Phase 3	cisplatin;fluorouracil
13	Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer	Completed	NCT00020787	Phase 3	cisplatin;fluorouracil
14	Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer	Completed	NCT00861094	Phase 2, Phase 3	cisplatin;5-FU;oxaliplatin;Folinic Acid
15	Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy	Completed	NCT01243398	Phase 3
16	Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery	Completed	NCT01107639	Phase 3	cisplatin;docetaxel
17	Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer	Completed	NCT00978549	Phase 3	docetaxel;steroid therapy
18	Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer	Completed	NCT00052910	Phase 3	cisplatin;epirubicin hydrochloride;fluorouracil;leucovorin calcium
19	Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus	Recruiting	NCT02509286	Phase 3	5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
20	NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)	Recruiting	NCT01726452	Phase 3	Epirubicin;Cisplatin;5 Flourouracil/ Capecitabine;Paclitaxel;Carboplatin
21	Efficacy and Safety Study of the Combined Modality Therapy in Adenocarcinoma of the Esophago-gastric Junction	Recruiting	NCT01523015	Phase 2, Phase 3
22	A Randomized, Controlled, Multicenter Study to Compare Preoperative Radiochemotherapy With Preoperative Chemotherapy in Patients With Locally Advanced Gastric or Esophagogastric Junction Adenocarcinoma	Recruiting	NCT03013010	Phase 3	Tegafur-Gimeracil-Oteracil Potassium;Oxaliplatin
23	Clinical Study of Time Optimizing of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer	Recruiting	NCT02628665	Phase 3	photosensitizer(photofrin)
24	Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery	Recruiting	NCT03604991	Phase 2, Phase 3	Carboplatin;Paclitaxel
25	Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer	Active, not recruiting	NCT01196390	Phase 3	Carboplatin;Paclitaxel
26	Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer	Not yet recruiting	NCT03801876	Phase 3	Carboplatin;Paclitaxel
27	Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma	Unknown status	NCT00964080	Phase 1, Phase 2	MBP-426/Leucovorin/5-FU
28	The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma	Unknown status	NCT00674167	Phase 2	Docetaxel;Cisplatin;Capecitabine
29	Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia	Unknown status	NCT01362127	Phase 2	Chemotherapy
30	Tethered Capsule Endoscope in Screening Participants for Barrett Esophagus	Unknown status	NCT00903136	Phase 1, Phase 2
31	Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus	Unknown status	NCT00003326	Phase 2	paclitaxel
32	Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer	Unknown status	NCT00006472	Phase 2	carboplatin;fluorouracil;paclitaxel
33	Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Cancer of the Stomach or Esophagus	Unknown status	NCT00005607	Phase 2	FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
34	Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer	Unknown status	NCT00004236	Phase 2	pegylated liposomal doxorubicin hydrochloride
35	Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery	Unknown status	NCT00005876	Phase 2	rubitecan
36	Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma	Completed	NCT00220103	Phase 2	epirubicin, capecitabine, cisplatin
37	Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma	Completed	NCT00583674	Phase 2	AMG 386 placebo;AMG 386 10mg/kg;AMG 386 3mg/kg;Cisplatin;Capecitabine;Cisplatin;Capecitabine;Cisplatin;Capecitabine
38	Effects Of Lapatinib (GW572016) In Patients With Relapsed Adenocarcinoma Of The Esophagus	Completed	NCT00259987	Phase 2	Lapatinib (GW572016) oral tablets
39	3-AP Plus Cisplatin in Treating Patients With Recurrent or Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction	Completed	NCT00077545	Phase 2	triapine;cisplatin
40	A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects	Completed	NCT02096666	Phase 1, Phase 2	AMG 337
41	Phase II Study of Irinotecan and Panitumumab	Completed	NCT00836277	Phase 2	Panitumumab;Irinotecan
42	Irinotecan in Treating Patients With Esophageal or Stomach Cancer	Completed	NCT00003748	Phase 2	irinotecan hydrochloride
43	Study of Erlotinib and Chemotherapy for Unresectable or Metastatic Cancer of the Esophagus and Gastric Cardia	Completed	NCT00591123	Phase 2	FOLFOX and Erlotinib
44	Irinotecan, Cisplatin, Bevacizumab, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Esophageal Cancer	Completed	NCT00354679	Phase 2	cisplatin;irinotecan hydrochloride
45	Capecitabine With or Without Sunitinib Malate as First-Line Therapy in Treating Patients With Metastatic Cancer of the Esophagus or Gastroesophageal Junction	Completed	NCT00891878	Phase 2	capecitabine;sunitinib malate
46	Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus	Completed	NCT00066716	Phase 2	carboplatin;celecoxib;paclitaxel
47	Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach	Completed	NCT00020761	Phase 2	irinotecan hydrochloride;paclitaxel
48	Combination Chemotherapy After Surgery in Treating Patients With Cancer of the Esophagus or Stomach	Completed	NCT00003237	Phase 2	cisplatin;paclitaxel
49	Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer	Completed	NCT00985192	Phase 2	everolimus
50	Docetaxel, Oxaliplatin, Capecitabine, Fluorouracil, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction	Completed	NCT00938470	Phase 2	capecitabine;docetaxel;fluorouracil;oxaliplatin

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Sources

Genetic Tests for Esophagus Adenocarcinoma

Sources

Anatomical Context for Esophagus Adenocarcinoma

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

⁴²

Breast, Liver, Colon, Bone, Testes, Lung, Lymph Node

Sources

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

(show all 20)

#	Title	Authors	Year
1	The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. ( 28184414 )	Kojima K...Watanabe M	2017
2	Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. ( 28049580 )	Xi T...Zhang G	2017
3	C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis. ( 27636117 )	Ren JL...Wang YX	2017
4	Preliminary evaluation for Bit1 as a potential biomarker for squamous cell carcinoma and adenocarcinoma of esophagus. ( 28488526 )	Chen J...Fan T	2017
5	In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. ( 24708360 )	Realdon S...Battaglia G	2015
6	Four cases of adenocarcinoma of esophagus with co-existing hydatid cyst of liver which caused delayed management of carcinoma esophagus. ( 24869991 )	Ghosh JK...Jain AK	2015
7	Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? ( 26185881 )	Mahmud B...Mohamadreza ZK	2014
8	Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray. ( 24519530 )	Wang HB...Li M	2014
9	Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus. ( 22875307 )	Pretto G...Meurer L	2013
10	Esophagogastric metaplasia relates to nodal metastases in adenocarcinoma of esophagus and cardia. ( 23434259 )	Ruffato A...Frassineti L	2013
11	Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). ( 22467322 )	Lukaszewicz-Zaj?c M...Szmitkowski M	2012
12	Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. ( 22509480 )	Yang L...Xie J	2012
13	Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. ( 21166737 )	Wang F...Fu YK	2011
14	Gene expression profiling of esophageal cancer: comparative analysis of Barrett's esophagus, adenocarcinoma, and squamous cell carcinoma. ( 17236199 )	Greenawalt DM...Phillips WA	2007
15	Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. ( 16985029 )	Chak A...Eng C	2006
16	WITHDRAWN: Expression of p53, p63, and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus☆,☆☆ ( 16126170 )	Cui R...Hainaut P	2005
17	Motor neuronopathy associated with adenocarcinoma of esophagus. ( 15129881 )	Khealani BA...Wasay M	2004
18	Ultrasound-guided fine-needle aspiration diagnosis of adenocarcinoma of esophagus with signet-ring cell features arising in Barrett's esophagus: a case report. ( 9664184 )	Baloch Z...Gupta PK	1998
19	Meningeal carcinomatosis in patient with esophagus adenocarcinoma. ( 9105327 )	Girola SS...Mazzone A	1997
20	"Barrett's esophagus" adenocarcinoma: a case report. ( 7431687 )	Nakamura T...Nagamachi Y	1980

Sources

Genes for Esophagus Adenocarcinoma

Genes related to Esophagus Adenocarcinoma (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	HNF1A-AS1	HNF1A Antisense RNA 1	RNA Gene	154.21	Experimental evidence: Expression ⁴⁰ DISEASES inferred ¹⁵	24000294
2	AFAP1-AS1	AFAP1 Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ⁴⁰	23333711
3	MIR143	MicroRNA 143	RNA Gene	50	Unspecified ⁴⁸	20301167
4	MIR145	MicroRNA 145	RNA Gene	50	Unspecified ⁴⁸	20301167
5	MIR21	MicroRNA 21	RNA Gene	50	Unspecified ⁴⁸	20301167
6	MIR215	MicroRNA 215	RNA Gene	50	Unspecified ⁴⁸	20301167
7	TP53	Tumor Protein P53	Protein Coding	23.75	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
8	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	22.35	DISEASES inferred ¹⁵ GeneCards inferred via : Variants (show sections)
9	SMAD4	SMAD Family Member 4	Protein Coding	17.08	GeneCards inferred via : Variants (show sections)
10	ATP12A	ATPase H+/K+ Transporting Non-Gastric Alpha2 Subunit	Protein Coding	16.65	DISEASES inferred ¹⁵
11	ATP4A	ATPase H+/K+ Transporting Subunit Alpha	Protein Coding	16.65	DISEASES inferred ¹⁵
12	CDO1	Cysteine Dioxygenase Type 1	Protein Coding	16.47	GeneCards inferred via : Publications (show sections)
13	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	15.36	DISEASES inferred ¹⁵
14	CDX2	Caudal Type Homeobox 2	Protein Coding	14.97	DISEASES inferred ¹⁵

Sources

Variations for Esophagus Adenocarcinoma

Sources

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Sources

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Gastric cancer ³⁸ Show member pathways Breast cancer ³⁸ Hepatocellular carcinoma ³⁸	12.29	CDX2 ERBB2 SMAD4 TP53
2	Colorectal Cancer Metastasis ⁶⁵	11.65	PTGS2 SMAD4 TP53
3	MicroRNAs in cancer ³⁸	11.64	ERBB2 MIR143 MIR145 MIR21 MIR215 PTGS2
4	DNA Damage Response (only ATM dependent) ¹	11.39	ERBB2 SMAD4 TP53
5	Hepatitis C and Hepatocellular Carcinoma ¹	10.84	PTGS2 SMAD4 TP53

Sources

GO Terms for Esophagus Adenocarcinoma

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 15)

#	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of cell proliferation	GO:0008285	9.81	MIR21 PTGS2 SMAD4 TP53
2	positive regulation of protein kinase B signaling	GO:0051897	9.71	ERBB2 MIR143 MIR21
3	negative regulation of angiogenesis	GO:0016525	9.63	MIR143 MIR145 MIR21
4	regulation of ERK1 and ERK2 cascade	GO:0070372	9.55	ERBB2 MIR145
5	positive regulation of vascular associated smooth muscle cell migration	GO:1904754	9.52	MIR143 MIR21
6	regulation of smooth muscle contraction	GO:0006940	9.49	MIR143 MIR145
7	cellular sodium ion homeostasis	GO:0006883	9.48	ATP12A ATP4A
8	establishment or maintenance of transmembrane electrochemical gradient	GO:0010248	9.43	ATP12A ATP4A
9	cellular potassium ion homeostasis	GO:0030007	9.4	ATP12A ATP4A
10	sodium ion export across plasma membrane	GO:0036376	9.37	ATP12A ATP4A
11	angiotensin-activated signaling pathway	GO:0038166	9.32	MIR143 MIR145
12	aorta smooth muscle tissue morphogenesis	GO:0060414	9.26	MIR143 MIR145
13	regulation of phenotypic switching	GO:1900239	9.16	MIR143 MIR145
14	establishment or maintenance of cell type involved in phenotypic switching	GO:0044663	8.96	MIR143 MIR145
15	negative regulation of cardiac muscle hypertrophy	GO:0010614	8.8	MIR145 MIR21 SMAD4

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygen	GO:0016702	9.16	CDO1 PTGS2
2	sodium:potassium-exchanging ATPase activity	GO:0005391	8.96	ATP12A ATP4A
3	potassium:proton exchanging ATPase activity	GO:0008900	8.62	ATP12A ATP4A

Sources

Sources for Esophagus Adenocarcinoma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FDA Approved Drugs

²⁰ FMA

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ Genetics Home Reference

²⁷ GenomeRNAi

²⁸ GEO DataSets

²⁹ GO

³⁰ GTR

³¹ HGMD

³² HMDB

³³ HPO

³⁴ ICD10

³⁵ ICD10 via Orphanet

³⁶ ICD9CM

³⁷ IUPHAR

³⁸ KEGG

³⁹ LifeMap

⁴⁰ LncRNADisease

⁴¹ LOVD

⁴² MalaCards

⁴³ MedGen

⁴⁴ MedlinePlus

⁴⁵ MeSH

⁴⁶ MESH via Orphanet

⁴⁷ MGI

⁴⁸ miR2Disease

⁴⁹ NCBI Bookshelf

⁵⁰ NCI

⁵¹ NCIt

⁵² NDF-RT

⁵³ NIH Clinical Center

⁵⁴ NIH Rare Diseases

⁵⁵ NINDS

⁵⁶ Novoseek

⁵⁷ Novus Biologicals

⁵⁸ OMIM

⁵⁹ OMIM via Orphanet

⁶⁰ Orphanet

⁶¹ PathCards

⁶² PharmGKB

⁶³ PubMed

⁶⁴ PubMed Health

⁶⁵ QIAGEN

⁶⁶ R&D Systems

⁶⁷ Reactome

⁶⁸ Sino Biological

⁶⁹ SNOMED-CT

⁷⁰ SNOMED-CT via HPO

⁷¹ SNOMED-CT via Orphanet

⁷² TGDB

⁷³ Tocris

⁷⁴ UMLS

⁷⁵ UMLS via Orphanet

⁷⁶ UniProtKB/Swiss-Prot

⁷⁷ Wikipedia